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Background 	

There is a rich literature in clinical psychology, psychiatry 
and neurology of single patient studies. Until now, however, 
such studies have focused on the parallel areas of clinical 
neuropsychiatry,  personal  genomics  and  brain-machine 
interfaces. 	

	

Methods 	

Detailed  phenotyping  and  clinical  evaluations  were 
conducted  over  a  four-year  period  for  a  single  individual 
with severe mental illness. His genome was sequenced in the 
Illumina  Whole  Genome  Sequencing  Clinical  Laboratory 
Improvement Amendments (CLIA)-certified laboratory. This 
person was implanted with the Medtronic Reclaim® Deep 
Brain Stimulation 	
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( DBS ) Therapy device for Obsessive Compulsive Disorder ( OCD ). 
Programming of the device and psychiatric assessments occurred in an 
outpatient setting for over two years.  	

	

Results  	

We report here the detailed phenotypic characterization, clinical-grade 
whole genome sequencing (WGS), and two year outcome of a man with 
severe  obsessive  compulsive  disorder  treated  with  deep  brain 
stimulation (DBS) targeting the nucleus accumbens / anterior limb of 
the internal capsule (ALIC). Since implantation, this man has reported 
steady improvement, highlighted by a steady decline in his Yale-Brown 
Obsessive Compulsive Scale (YBOCS) score from ~38 to a score of 
~25.  A rechargeable  Activa  RC neurostimulator  battery  has  been  of 
major benefit in terms of facilitating a degree of stability and control 
over the stimulation. His psychiatric symptoms reliably worsen within	

hours  of  the  battery  becoming  depleted,  thus  providing  confirmatory 
evidence for the efficacy of DBS for OCD in this person. Whole genome 
sequencing revealed that he is a heterozygote for the p.Val66Met variant in 
BDNF, encoding a member of the nerve growth factor family, and which has 
been found to predispose carriers to various psychiatric illnesses. He carries 
the p.Glu429Ala allele in methylenetetrahydrofolate reductase (MTHFR) and 
the p.Asp7Asn allele  in ChAT, encoding choline O-acetyltransferase,  with 
both  alleles  having  been  shown  to  confer  an  elevated  susceptibility  to 
psychoses.  We  have  found  thousands  of  other  variants  in  his  genome, 
including  pharmacogenetic  variants,  and  have  archived  and  offered  the 
clinical  sequencing data  to  him,  so  that  he  and others  can re-analyze  his 
genome  for  years  to  come.  As  this  individual  is  a  U.S.  Veteran,  we  are 
working  with  the  VA to  incorporate  his  genomic  data  into  the  electronic 
medical  record,  VistA,  which  is  of  relevance  to  the  One Million  Veteran 
Program.	

Conclusions	

To  our  knowledge,  this  is  the  first  study  in  the  clinical 
neurosciences  including  1)  clinical-grade  WGS  with 
management  and  return  of  genetic  results  for  a  person  with 
severe  mental  illness  and  2)  detailed  neuropsychiatric 
phenotyping  and  individualized  treatment  with  deep  brain 
stimulation for his OCD. His WGS results and positive outcome 
with DBS for OCD is one example of individualized medicine in 
neuropsychiatry,  including  genomics-guided  preventive  efforts 
and brain-implantable devices.  This  is  also an example of  the 
split  model  for  clinical  genomics  involving  separate  clinical-
grade processes for sample collection, sequencing, analysis, and 
clinical interpretation.	
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Figure 2.   Yale Brown Obsessive Compulsive Scale (YBOCS) scores were measured 
for M.A  over a three year and seven months period of time.  A time series plot (A) 
shows a steady decline in YBOCS scores over the period of time spanning his DBS surgery 
(s) and treatment.   Incremental adjustments to neurostimulator voltage are plotted over a 
period of time following DBS surgery (A).  Mean YBOCS scores are plotted for sets of 
measurements taken before and after his Deep Brain Stimulation (DBS) surgery (B).  A 
one-tailed  unpaired  t  test  with  Welch’s  correction  results  in  a  p  value  of 
0.0056,  demonstrating  a significant difference  between YBOCS scores measured before 
and after the time of surgery.	

Figure 1. Illumina CLIA Whole genome sequencing data summarized in the form of a 
Circos plot. We show here a summary of the genomic coordinates corresponding to the 
344  genes  that  were  clinically  evaluated  by  the  Illumina  CLIA WGS  pipeline,  the 
frequency of IGN validated SNVs across the genome (plotted in red) and a summary of 
highly confident copy number variations (CNVs) that were simultaneously detected by the 
Estimation  by  Read  Depth  with  SNVs  (ERDS)  and  Copy  Number  Analysis  Method 
(CNAM) detection methods (plotted in black).  Duplications and deletions are depicted as 
elevations and declinations, respectively. None of the identified CNVs have any published 
association with mental illness.	

Table 1.  A summary of three clinically relevant alleles found in the sequencing results of M.A. Mutations in MTHFR, BDNF,  and ChAT 
were found to be of potential clinical relevance for this person, as they are all implicated in contributing to the susceptibility and development 
of many neuropsychiatric disorders that resemble those present within M.A.  A brief summary of the characteristics of each mutation is shown, 
including the gene name, genomic coordinates, amino acid change, zygosity, mutation type, estimated population frequency and putative 
clinical significance.	

!
Gene name Genomic coordinates 
Amino acid 
change Zygosity 
Mutation 
type 
Population 
Frequency Clinical significance 
MTHFR chr1: 11854476 Glu>Ala heterozygous non-synon T:77% G:23% 
Susceptibility to psychoses, schizophrenia 
occlusive vascular disease, neural tube 
defects, colon cancer, acute leukemia, and 
methylenetetra-hydrofolate reductase def-
iciency  
BDNF chr11: 27679916 Val>Met heterozygous non-synon C:77% T:23% 
Susceptibility to OCD, psychosis, and 
diminished response to exposure therapy  
CHAT chr10: 50824117 Asp>Asn heterozygous non-synon G:85% A:15% 
Susceptibility to schizophrenia and other 
psychopathological disorders. 
